EUVIMEDΑνακαλύψτε το EUVIMED
StudienprotokollOpen access

Efficacy of Preventive Pressurized Intraperitoneal Aerosol Chemotherapy in Patients With Locally Advanced Gastric Cancer: Protocol for a Prospective Controlled Trial

Wirksamkeit einer prophylaktischen pressurisierten intraperitonealen Aerosolchemotherapie bei Patient:innen mit lokal fortgeschrittenem Magenkarzinom: Protokoll einer prospektiven kontrollierten Studie

Altay Kerimkulov iD, Talgat Uskenbayev iD, Tomiris Sarina iD, Meiram Mamlin iD, Sanzhar Shalekenov iD, Gulfairus Yessenbayeva iD, Temirlan Kainazarov iD, Zhandos Burkitbayev iD, Baiduisen Ussipbekov iD, Dina Kovalchuk iD, Akhror Rakhmankulov iD, Aidana Rakhmankulova iD and 1 more

JMIR Research Protocols · 2025-11-11 · 14 · e78053

DOI: 10.2196/78053 ↗

Auf einen Blick

Geplant ist zu prüfen, ob prophylaktisches PIPAC zusätzlich zur Standardtherapie die Rate peritonealer Metastasen bei lokal fortgeschrittenem Magenkarzinom senkt. Die Studie ist als kontrollierte, nicht randomisierte Studie angelegt.

Fragestellung

Reduziert die Zugabe von prophylaktischem PIPAC zur Standardtherapie die Inzidenz peritonealer Metastasen bei lokal fortgeschrittenem Magenkarzinom?

Methode

Einzentrische, nicht randomisierte kontrollierte Studie mit geplanter Einschlusszahl von 160 Patient:innen; 2 Gruppen: PIPAC + perioperative Chemotherapie + Gastrektomie mit D2-Lymphadenektomie vs. perioperative Chemotherapie + Gastrektomie mit D2-Lymphadenektomie.

Ergebnisse

Bis September 2025 wurden 102 Teilnehmende eingeschlossen. Rekrutierung geplant von Januar 2025 bis Dezember 2026; keine Interimsanalysen; primäre Ergebnisse für Q1 2027 geplant.

Schlussfolgerung der Autor:innen

Die Autor:innen vermuten, dass der neoadjuvante Einsatz von PIPAC die Inzidenz peritonealer Metastasen senken und langfristige Überlebensoutcomes verbessern könnte. Die Studie soll die Praktikabilität und Durchführbarkeit als prophylaktische Technik klären.

Kernaussagen

  • Primärer Endpunkt: Inzidenz peritonealer Metastasen
  • Geplante Stichprobe: 160 Patient:innen
  • Bis September 2025 waren 102 Teilnehmende eingeschlossen

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Studienprotokoll in JMIR Research Protocols, published online on 2025-11-11. Written by Altay Kerimkulov and 12 co-authors. Institution: National Research Oncology Center, Astana, null, Kazakhstan. Major MEDLINE topics: Stomach Neoplasms, Peritoneal Neoplasms. Cited 2 times so far (Crossref); 26 references. The full text is freely available in PubMed Central.

Auf einen BlickΠερίληψηSubjectsΒιβλιογραφικά στοιχείαCiteRelated studies

Abstract (original language)

Background

Gastric cancer is a serious health issue both globally and in Kazakhstan. Worldwide, gastric cancer ranks fifth in incidence, with the highest rates reported in East Asia, the Andes of South America, and Eastern Europe, while the lowest rates are reported in North America, Northern Europe, Africa, and Southeast Asia. Over 70% of the cases occur in resource-limited countries. In Kazakhstan, gastric cancer ranks third in morbidity and second in mortality, representing a serious clinical and social problem. Annually, 1600 deaths from malignant gastric neoplasms are registered. Peritoneal metastasis is considered one of the most severe complications of gastric cancer and has long been regarded as its terminal stage. The average life expectancy of patients with peritoneal metastasis is only 3-6 months, reflecting a high mortality rate and the limited efficacy of current treatments.

Objective

We hypothesize that the prophylactic use of pressurized intraperitoneal aerosol chemotherapy (PIPAC) may reduce the incidence of peritoneal metastasis. The aim of this study is to evaluate the incidence of peritoneal metastasis following prophylactic PIPAC in patients with gastric cancer. The primary goal of this research is to evaluate whether adding prophylactic PIPAC to standard treatment before neoadjuvant chemotherapy can reduce the incidence of peritoneal metastasis in patients with locally advanced gastric cancer.

Methods

This study is a single-center nonrandomized controlled trial with a planned enrollment of 160 patients. All participants will be included in one of the 2 groups: intervention group (PIPAC + perioperative chemotherapy + gastrectomy with D2 lymphadenectomy) or control group (perioperative chemotherapy + gastrectomy with D2 lymphadenectomy). The primary end point is the incidence of peritoneal metastasis, and the secondary end points are overall survival, recurrence-free survival, treatment-related adverse events, and personal satisfaction.

Results

As of September 2025, this study is funded and recruiting; 102 participants have already been enrolled. Recruitment is planned to be performed between January 2025 and December 2026. No interim analyses have been performed; primary results are planned for Q1 2027. The manuscript is expected to be published by Q4 2027.

Conclusions

Compared to standard chemotherapy, PIPAC has been reported to significantly improve survival rates in patients with peritoneal metastasis of gastric origin. We suggest that the neoadjuvant use of PIPAC may reduce the incidence of peritoneal metastasis and improve long-term survival outcomes. The results of our study will provide key information on the practicality and viability of PIPAC as a prophylactic technique for preventing the progression of gastric cancer. Trial Registration ClinicalTrials.gov NCT06784765; https://clinicaltrials.gov/study/NCT06784765 International Registered Report Identifier (IRRID) PRR1-10.2196/78053

Subjects

MeSH terms (MEDLINE)

Stomach NeoplasmsPeritoneal NeoplasmsHumansProspective StudiesAerosolsMaleFemaleNeoadjuvant Therapy

Author keywords

HIPECPIPACchemotherapygastric cancerhyperthermic intraperitoneal chemotherapyintraperitoneal treatmentoncologyperitoneal metastasispressurized intraperitoneal aerosol chemotherapy

Substances

Aerosols

Authors and institutions

  • National Research Oncology Center, Astana, null, Kazakhstan.
  • Municipal hospital No. 1, Astana, null, Kazakhstan.
  • Nazarbayev University, Astana, null, Kazakhstan.

ORCID profiles: Altay Kerimkulov, Talgat Uskenbayev, Tomiris Sarina, Meiram Mamlin, Sanzhar Shalekenov, Gulfairus Yessenbayeva, Temirlan Kainazarov, Zhandos Burkitbayev, Baiduisen Ussipbekov, Dina Kovalchuk, Akhror Rakhmankulov, Aidana Rakhmankulova, Abduzhappar Gaipov

Cite

APA

Kerimkulov, A., Uskenbayev, T., Sarina, T., Mamlin, M., Shalekenov, S., Yessenbayeva, G., Kainazarov, T., Burkitbayev, Z., Ussipbekov, B., Kovalchuk, D., Rakhmankulov, A., Rakhmankulova, A., & Gaipov, A. (2025). Efficacy of Preventive Pressurized Intraperitoneal Aerosol Chemotherapy in Patients With Locally Advanced Gastric Cancer: Protocol for a Prospective Controlled Trial. JMIR Research Protocols, 14, e78053. https://doi.org/10.2196/78053

Vancouver

Kerimkulov A, Uskenbayev T, Sarina T, Mamlin M, Shalekenov S, Yessenbayeva G, et al. Efficacy of Preventive Pressurized Intraperitoneal Aerosol Chemotherapy in Patients With Locally Advanced Gastric Cancer: Protocol for a Prospective Controlled Trial. JMIR Research Protocols. 2025;14:e78053. doi:10.2196/78053

BibTeX
@article{Kerimkulov2025,
  author = {Kerimkulov, Altay and Uskenbayev, Talgat and Sarina, Tomiris and Mamlin, Meiram and Shalekenov, Sanzhar and Yessenbayeva, Gulfairus and Kainazarov, Temirlan and Burkitbayev, Zhandos and Ussipbekov, Baiduisen and Kovalchuk, Dina and Rakhmankulov, Akhror and Rakhmankulova, Aidana and Gaipov, Abduzhappar},
  title = {Efficacy of Preventive Pressurized Intraperitoneal Aerosol Chemotherapy in Patients With Locally Advanced Gastric Cancer: Protocol for a Prospective Controlled Trial},
  journal = {JMIR Research Protocols},
  year = {2025},
  volume = {14},
  pages = {e78053},
  doi = {10.2196/78053}
}
Start for free →